Scholarlink

Purpose <p>The COVID-19 pandemic was associated with a decrease in the incidence of breast cancers in 2020 and was expected to be associated with advanced stage at presentation in the post-pandemic era. The primary objective of this study is to compare stage at presentation and biological tumor characteristics of breast cancers treated before and after the initial phase of the COVID pandemic.</p> Methods <p>A retrospective chart review was performed of patients diagnosed with breast cancer within a single New York City health care system between March-August 2019 (pre-pandemic; PP) and March – August 2021 (post- acute phase pandemic; PAP).</p> Results <p>There were 381 patients with breast cancer in the 2019 PP cohort and 558 patients diagnosed in the 2021 PAP cohort. The PAP cohort was more likely to have a larger median tumor size (16&#xa0;mm vs 12&#xa0;mm, <i>p</i> &lt; 0.001) and more tumors &gt; 2&#xa0;cm at surgery (OR 1.48, <i>p</i> = .048). PAP patients were more likely to have node positive disease at surgery (OR 2.54, <i>p</i> = 0.0003), grade 3 tumors (OR 1.29, <i>p</i> = 0.046) and pathologic stage II or III disease at upfront surgery (OR 2.89, <i>p</i> = 0.003). The PAP cohort was also more likely to have &gt; 24&#xa0;months since their last imaging test (<i>p</i> &lt; 0.001) and less likely to have their breast cancer detected by screening breast MRI (OR .36, <i>p</i> = .016).</p> Conclusion <p>Breast cancer diagnosed in the post-acute pandemic period had a greater odds of having a &gt; 24-month interval since their last screening mammogram and pathologic stage II &amp; III disease than pre-pandemic patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Breast cancer patients treated at a New York City academic health system during the COVID-19 pandemic in 2021 had delayed presentations and more advanced disease than pre-pandemic cases

  • 期刊论文

  • 发表日期：

    2025年11月27日

查看全文
  • Stephanie Bernik,
  • Tara M. Balija,
  • Daniel Kim,
  • Adriano Cuadros,
  • Daniella Jackson,
  • Jean Hee Lee,
  • Niathi Kona,
  • Simran Malhotra,
  • Martina Lopez May,
  • Jaan Nandwani,
  • Daniella Nevid,
  • Kaothar Oladoja,
  • Borna Mohabbatizadeh,
  • Erin Moshier,
  • Elisa Port

摘要

Purpose

The COVID-19 pandemic was associated with a decrease in the incidence of breast cancers in 2020 and was expected to be associated with advanced stage at presentation in the post-pandemic era. The primary objective of this study is to compare stage at presentation and biological tumor characteristics of breast cancers treated before and after the initial phase of the COVID pandemic.

Methods

A retrospective chart review was performed of patients diagnosed with breast cancer within a single New York City health care system between March-August 2019 (pre-pandemic; PP) and March – August 2021 (post- acute phase pandemic; PAP).

Results

There were 381 patients with breast cancer in the 2019 PP cohort and 558 patients diagnosed in the 2021 PAP cohort. The PAP cohort was more likely to have a larger median tumor size (16 mm vs 12 mm, p < 0.001) and more tumors > 2 cm at surgery (OR 1.48, p = .048). PAP patients were more likely to have node positive disease at surgery (OR 2.54, p = 0.0003), grade 3 tumors (OR 1.29, p = 0.046) and pathologic stage II or III disease at upfront surgery (OR 2.89, p = 0.003). The PAP cohort was also more likely to have > 24 months since their last imaging test (p < 0.001) and less likely to have their breast cancer detected by screening breast MRI (OR .36, p = .016).

Conclusion

Breast cancer diagnosed in the post-acute pandemic period had a greater odds of having a > 24-month interval since their last screening mammogram and pathologic stage II & III disease than pre-pandemic patients.